US Generic Injectables Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

US Generic Injectables Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

  • May 2022 •
  • 140 pages •
  • Report ID: 5083189 •
  • Format: PDF
The US generic injectables market reached a value of US$ 16.3 Billion in 2021. Looking forward, the analyst expects the market to reach US$ 29.6 Billion by 2027, exhibiting a CAGR of 10.21% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Generic injectables refer to bioequivalents of branded drugs that are not protected by patents. They are used for rapidly transporting the drug into the body, bypassing the first-pass metabolism. Since they have a similar quality, dosage, strength, effect and active ingredient, generic injectables are as safe and effective as innovator injectables. They are widely used in the United States on account of the rise in the prevalence of lifestyle ailments due to sedentary lifestyles, non-nutritive diet and aging population. They are utilized in the treatment of diseases such as cancer, diabetes, osteoporosis, osteoarthritis, rheumatoid arthritis, respiratory and cardiovascular disorders.

The US is witnessing a rise in the demand for generic injectables on account of increasing investment by the US Government for the development of generic drugs. It is focusing on promoting generic injectables to reduce healthcare expenditure in the country. Further, drug shortages in confluence with speedy approvals by the USFDA are expected to boost the manufacturing of these drugs. Moreover, several branded injectables firms are also anticipated to lose their patient protection in the upcoming years, thereby offering numerous remunerative opportunities to the generic injectables manufacturers.

Key Market Segmentation:
the analyst provides an analysis of the key trends in each sub-segment of the US generic injectables market, along with forecasts at the for the period 2022-2027. Our report has categorized the market based on therapeutic area, containers and distribution channel.

Breakup by Therapeutic Area:
Oncology
Anesthesia
Anti-Infectives
Parenteral Nutrition
Cardiovascular

Breakup by Containers:
Vials
Ampoules
Premix
Prefilled Syringes

Breakup by Distribution Channel:
Hospitals
Retail Pharmacy

Competitive Landscape:
The market is highly concentrated in nature with the presence of only a few top manufacturers who compete against one another in terms of prices and quality.



Key Questions Answered in This Report:

How has the US generic injectables market performed so far and how will it perform in the coming years?
What are the major therapeutic areas in the US generic injectables industry?
What has been the impact of COVID-19 on the US generic injectables industry?
What are the several containers used in the US generic injectables industry?
What are the major distribution channels in the US generic injectables industry?
What are the various stages in the value chain of the US generic injectables industry?
What are the key driving factors and challenges in the US generic injectables industry?
What is the structure of the US generic injectables industry and who are the key players?
What is the degree of competition in the US generic injectables industry?
What are the profit margins in the US generic injectables industry?
What are the key requirements for setting up generic injectables manufacturing plant?
How are generic injectables manufactured?
What are the various unit operations involved in generic injectables manufacturing plant?
What is the total size of land required for setting up generic injectables manufacturing plant?
What are the machinery requirements for setting up generic injectables manufacturing plant?
What are the raw material requirements for setting up generic injectables manufacturing plant?
What are the packaging requirements for generic injectables?
What are the transportation requirements for generic injectables?
What is the time required to break-even?